Industry Support of CME - the Solution, not the Problem?
This article was originally published in Clinica
As doctors in the US brace themselves for the additional 30 million patients that the new healthcare reform law promises to channel into the system, a key mechanism for advancing their medical knowledge and performance is facing tumultuous times.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.